Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus XULANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus XULANE.
IMPLANON vs XULANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
Ethinyl estradiol and norelgestromin (the active metabolites of norgestimate) suppress gonadotropin release, inhibiting ovulation and increasing cervical mucus viscosity, impairing sperm penetration.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
Apply 1 patch (20 cm² containing 600 mcg ethinyl estradiol and 6 mg norelgestromin) transdermally once weekly for 3 weeks, followed by 1 patch-free week.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Terminal elimination half-life is 4.5 hours; in severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment.
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Primarily renal (approximately 60-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Contraceptive
Contraceptive